Group 1 - The article discusses the encouragement from Faruq & Faruq, LLP for investors who suffered losses exceeding $75,000 in LifeMD to reach out for legal options [1] - The specified time frame for the losses is between May 7, 2025, and August 5, 2025 [1] - Contact information for legal inquiries is provided, including phone numbers for direct communication with partner Josh Wilson [1]

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1][2]. Group 1: Allegations and Claims - The lawsuit claims that defendants materially overstated LifeMD's competitive position [2]. - It is alleged that defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [2]. - As a result, the statements made by defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the U.S. [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit due to allegations of materially false and misleading statements made by the company during the specified class period [1]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from May 7, 2025, to August 5, 2025, LifeMD's management overstated the company's competitive position [1]. - It is claimed that the company was reckless in raising its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [1]. - As a result, the statements made by the defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [1]. Class Action Details - Shareholders who purchased shares of LifeMD during the class period are encouraged to register for the class action, with a deadline set for October 25, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that led to artificial inflation of stock prices [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought LifeMD securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 27, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements regarding LifeMD's competitive position and failed to account for rising customer acquisition costs in their 2025 guidance [5]. - It is claimed that the defendants' statements about LifeMD's business operations and prospects were materially false and misleading, leading to investor damages when the true information became public [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and financial guidance [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $75,000 in LifeMD between May 7, 2025, and August 5, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against LifeMD, with a deadline of October 27, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against LifeMD - The complaint alleges that LifeMD and its executives materially overstated the company's competitive position and were reckless in raising the 2025 guidance without properly accounting for rising customer acquisition costs [6]. - LifeMD's revised guidance announced on August 5, 2025, projected total revenue in the range of $250 to $255 million, down from previous guidance of $268 to $275 million, leading to a 44.8% stock price drop on August 6, 2025 [7].

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements regarding LifeMD's competitive position and recklessly raised the company's 2025 guidance without properly accounting for rising customer acquisition costs [2]. - Allegations include that the defendants' statements about LifeMD's business operations and prospects were materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1][2]. Group 1: Allegations and Details - The lawsuit claims that defendants made false statements and concealed critical information regarding LifeMD's competitive position and financial guidance for 2025 [2]. - It is alleged that the defendants did not properly account for rising customer acquisition costs in LifeMD's RexMD segment and related to obesity treatment drugs, leading to misleading statements about the company's business and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request to be appointed as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during a specified class period [1][3]. Group 1: Allegations - The complaint alleges that during the class period from May 7, 2025, to August 5, 2025, LifeMD's management materially overstated the company's competitive position [3]. - It is claimed that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [3]. - As a result, the statements made by the defendants regarding LifeMD's business, operations, and prospects were materially false and misleading, lacking a reasonable basis at all relevant times [3]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is October 25, 2025, and they are encouraged to register promptly [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the lifecycle of the case [4]. - Participation in the case does not incur any cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that led to artificial inflation of stock prices [5].

Core Viewpoint - LifeMD, Inc. is facing a securities fraud class action lawsuit, with a deadline for investors to act by October 27, 2025 [1][3][4] Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Eastern District of New York on behalf of investors who purchased LifeMD securities between May 7, 2025, and August 5, 2025, alleging violations of the Securities Exchange Act of 1934 [3] - The allegations include misrepresentations regarding LifeMD's competitive position made by the company and certain senior officers [3] Group 2: Investor Participation - Investors who wish to serve as lead plaintiffs must file necessary documents by October 27, 2025, although participation as a lead plaintiff is not required to share in any potential recovery [4] - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [4] Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [5] - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [5]

NEW YORK , Sept. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). ...